Organon (OGN) FCF Payout Ratio Growth (1y) (2022 - 2026)
Organon (OGN) FCF Payout Ratio Growth (1y) (2022 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Cover Growth (1y) (Qtr) |
| 1 |
Gsk |
93,026,132.38 Bn |
93,026,127.42 Bn |
7.76 Bn |
-0.92% |
| 2 |
Eli Lilly |
1,022.62 Bn |
1,017.34 Bn |
16.22 Bn |
-94.03% |
| 3 |
Johnson & Johnson |
570.65 Bn |
548.59 Bn |
15.96 Bn |
141.61% |
| 4 |
AbbVie |
398.73 Bn |
389.38 Bn |
10.78 Bn |
-58.56% |
| 5 |
Merck |
295.53 Bn |
289.88 Bn |
12.09 Bn |
-58.88% |
| 6 |
Amgen |
186.30 Bn |
174.26 Bn |
5.87 Bn |
-29.55% |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
-29.45% |
| 8 |
Pfizer |
146.09 Bn |
133.32 Bn |
-1.21 Bn |
-18.46% |
| 9 |
Bristol Myers Squibb |
114.98 Bn |
104.53 Bn |
8.07 Bn |
128.23% |
| 10 |
Organon |
3.49 Bn |
2.37 Bn |
783.00 Mn |
-98.39% |
| Date | Value |
|---|
| Mar 31, 2026 |
-98.39% |
| Dec 31, 2025 |
-81.14% |
| Sep 30, 2025 |
-98.16% |
| Jun 30, 2025 |
-79.02% |
| Mar 31, 2025 |
-29.24% |
| Dec 31, 2024 |
-3.77% |
| Sep 30, 2024 |
108.08% |
| Jun 30, 2024 |
115.66% |
| Mar 31, 2024 |
117.35% |
| Dec 31, 2023 |
-35.85% |
| Sep 30, 2023 |
27.18% |
| Jun 30, 2023 |
-347.60% |
| Mar 31, 2023 |
36.08% |
| Dec 31, 2022 |
106.05% |
| Sep 30, 2022 |
26.72% |
